Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Oracle shares face continued pressure over debt and AI infrastructure costs, but Guggenheim's bullish $400 price target suggests potential for a multi-year rebound if execution risks are managed.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Oracle Corp. plans a colossal $45-$50 billion capital raise in 2026 to expand its cloud infrastructure, aiming to meet surging demand from AI giants like OpenAI and Nvidia. The move comes as the company's aggressive data center spending pushes its free cash flow negative, a condition projected to last for years.
Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
Fueled by surging global demand for its Hoka and Ugg brands, Deckers Outdoor Corp. posted a robust third-quarter performance that surpassed expectations, driving its stock price up sharply and assuaging recent Wall Street concerns over growth sustainability.
